ACTIVE

Abscint

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result363,8 k €+127,1 %over 1 year

Gross margin870,8 k €+231,9 %over 1 year

Equity5,6 M €+60,3 %over 1 year

Workforce2,7 ETP-10,0 %over 1 year

Identity

Source · BCE/KBO

Abscint is a Public limited company incorporated in 2020. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 2,7 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0749.828.410
Incorporation: 06/07/2020
Legal form: Public limited company
Registered office: Boulevard de Patience et Beaujonc 3 box 23
4000 Liège · WallonieSee on map
Contributed capital: 7 248 337,10 €
Latest accounts: 31/12/2025
Average workforce: 2,7 ETP

Activities (NACE)

72101Research and experimental development on natural sciences and engineering· main 72110Research and experimental development on biotechnology 86901Other human health activities 86910Other human health activities 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 5 filings

Trend over 5 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	870,8 k €	+232%	-660,2 k €	-101%	-328,2 k €	-31.4%	-249,7 k €	-98.7%	-125,7 k €
EBITDA	541,2 k €	+152%	-1 M €	-66.7%	-622,2 k €	-43.5%	-433,7 k €	-89.7%	-228,6 k €
Operating result	247,5 k €	+114%	-1,8 M €	+1.5%	-1,8 M €	-285%	-463,5 k €	-94.8%	-237,9 k €
Net result	363,8 k €	+127%	-1,3 M €	-32.4%	-1 M €	-118%	-463,6 k €	-94.9%	-237,9 k €
Balance sheet
Equity	5,6 M €	+60.3%	3,5 M €	-22.6%	4,5 M €	+246%	1,3 M €	+207%	422 k €
Total assets	6,8 M €	+60.3%	4,3 M €	-9.8%	4,7 M €	+227%	1,5 M €	+186%	507,3 k €
Cash	2,8 M €	+29.4%	2,1 M €	-28.1%	3 M €	+203%	985,9 k €	+171%	364,4 k €
Debts	1,3 M €	+60.6%	804,4 k €	+212%	257,5 k €	+67.0%	154,2 k €	+80.8%	85,3 k €
Other
Workforce	2,7 ETP	-10.0%	3,0 ETP		–		–		–

Valuation

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 3 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Koen DEWAELE	Director24/07/2023 → 10/11/2028
CBD Consulting0636.837.761Represented by Karine CLAUWAERT	Managing director10/11/2022 → 10/11/2028Director03/07/2020 → 2022 accountsended
Didier Allaer	Director10/11/2022 → 10/11/2028
Jacobus Boonen	Director08/02/2021 → 10/11/2028
NOSHAQ PARTNERS0808.219.836Represented by Marleen LIMBOURG	Director15/01/2022 → 10/11/2028
Qbic Venture Partners II0668.403.244Represented by Sara VANDENWIJNGAERT	Director10/11/2022 → 10/11/2028

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Marleen Keyaerts	Director10/11/2022 → 2022 accounts
QBIC Venture Partners0846.494.353Represented by Wim VAN CAMP	Director08/02/2021 → 2022 accounts
Tony Lahoutte	Director03/07/2020 → 2021 accounts

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège

Company	CBE no.
Aeroforge● Active	1044.274.185
AMPACIMON● Active	0827.990.317
Amyl Therapeutics● Active	0758.775.372
BECARV● Bankrupt	0840.777.885
BE.SPINE● Active	1013.110.857
CATALYA● Active	0727.648.171
CEFALY Technology● Active	0870.578.661
DERMAX● Active	0667.730.677
DIANOSIC● Active	1034.558.646
DW Cefaly Holding● Active	0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active	1023.778.481
EXO Biologics● Active	0732.982.379
ExoXpert● Active	1003.807.666
EYED PHARMA● Active	0508.599.605
Hirundo Biosciences● Active	0681.855.065
HolyFox Invest● Active	1010.693.181
Hyloris● Active	0669.738.676
Hyloris Developments● Active	0542.737.368
Hyloris Pharmaceuticals● Active	0674.494.151
Hyloris Therapeutics● Active	1025.029.385

Full financial information

Source · NBB

	2025	2024	2023	2022	2021
Type of account	Abridged model	Abridged model	Micro model	Micro model	Micro model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	03/07/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021
Length of the financial year	12 months	12 months	12 months	12 months	18 months
Filing date	06/07/2026	19/06/2025	17/06/2024	26/06/2023	01/07/2022
General meeting	17/06/2026	13/06/2025	14/06/2024	30/05/2023	27/06/2022
Currency of the financial year	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 5 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	17/06/2026	06/07/2026	French	PDF
Abridged model	31/12/2024	13/06/2025	19/06/2025	French	PDF
Micro model	31/12/2023	14/06/2024	17/06/2024	French	PDF
Micro model	31/12/2022	30/05/2023	26/06/2023	Dutch	PDF
Micro model	31/12/2021	27/06/2022	01/07/2022	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 3 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Koen DEWAELE	Director24/07/2023 → 10/11/2028
CBD Consulting0636.837.761Represented by Karine CLAUWAERT	Managing director10/11/2022 → 10/11/2028Director03/07/2020 → 2022 accountsended
Didier Allaer	Director10/11/2022 → 10/11/2028
Jacobus Boonen	Director08/02/2021 → 10/11/2028
NOSHAQ PARTNERS0808.219.836Represented by Marleen LIMBOURG	Director15/01/2022 → 10/11/2028
Qbic Venture Partners II0668.403.244Represented by Sara VANDENWIJNGAERT	Director10/11/2022 → 10/11/2028

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Marleen Keyaerts	Director10/11/2022 → 2022 accounts
QBIC Venture Partners0846.494.353Represented by Wim VAN CAMP	Director08/02/2021 → 2022 accounts
Tony Lahoutte	Director03/07/2020 → 2021 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates21/09/2026
Nominations et démissions
PDF
Capital / shares25/08/2026
CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION,
PDF
Capital / shares21/11/2025
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
PDF
Mandates14/02/2025
DEMISSIONS, NOMINATIONS
PDF
Capital / shares05/02/2024
CAPITAL, ACTIONS
PDF
Other06/10/2023
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Mandates03/10/2023
MAATSCHAPPELIJKE ZETEL - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates18/11/2022
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings5 filings

Mandates

Koen DEWAELE

CBD Consulting

Qbic Venture Partners II

NOSHAQ PARTNERS

Didier Allaer

Jacobus Boonen

QBIC Venture Partners

Marleen Keyaerts

Tony Lahoutte

202020212022202320242025202620272028

Abscint

Boulevard de Patience et Beaujonc 3 bte 23, 4000 LiègeBroustinlaan 67, 1083 Ganshoren

Director

Managing directorDirector

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Boulevard de Patience et Beaujonc 3 bte 23, 4000 LiègeCurrent	accounts 2023 → 2025	Accounts 2025 · 2026-00265334
Broustinlaan 67, 1083 Ganshoren	accounts 2021 → 2022	Accounts 2022 · 2023-00155716

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
AbscintCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00265334

Events

2025
Annual accounts 2025363,8 k €↑
2024
Annual accounts 2024-1,3 M €↓
2023
Annual accounts 2023-1 M €↓
2022
Annual accounts 2022-463,6 k €↓
2021
Annual accounts 2021-237,9 k €
06/07/2020
IncorporationPublic limited company

Abscint

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events